Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Homonymous Hemianopsia Due to Posterior Cortical Atrophy.

Pellegrini F, Lee AG, Zucchetta P.

Neuroophthalmology. 2017 Feb 15;41(3):154-158. doi: 10.1080/01658107.2016.1278556. eCollection 2017 Jun.

PMID:
28512507
2.

Can Salivary Acetylcholinesterase be a Diagnostic Biomarker for Alzheimer?

Bakhtiari S, Moghadam NB, Ehsani M, Mortazavi H, Sabour S, Bakhshi M.

J Clin Diagn Res. 2017 Jan;11(1):ZC58-ZC60. doi: 10.7860/JCDR/2017/21715.9192. Epub 2017 Jan 1.

3.

Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, Strittmatter SM; Alzheimer’s Disease Neuroimaging Initiative..

Acta Neuropathol. 2017 May;133(5):785-807. doi: 10.1007/s00401-017-1668-z. Epub 2017 Jan 9.

PMID:
28070672
4.

A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics.

Song L, Lachno DR, Hanlon D, Shepro A, Jeromin A, Gemani D, Talbot JA, Racke MM, Dage JL, Dean RA.

Alzheimers Res Ther. 2016 Dec 15;8(1):58.

5.

Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease.

Dean DC 3rd, Hurley SA, Kecskemeti SR, O'Grady JP, Canda C, Davenport-Sis NJ, Carlsson CM, Zetterberg H, Blennow K, Asthana S, Sager MA, Johnson SC, Alexander AL, Bendlin BB.

JAMA Neurol. 2017 Jan 1;74(1):41-49. doi: 10.1001/jamaneurol.2016.3232.

PMID:
27842175
6.

Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges.

Kim D, Kim YS, Shin DW, Park CS, Kang JH.

J Clin Neurol. 2016 Oct;12(4):381-392. doi: 10.3988/jcn.2016.12.4.381. Review.

7.

Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease.

Sogorb-Esteve A, García-Ayllón MS, Fortea J, Sánchez-Valle R, Lleó A, Molinuevo JL, Sáez-Valero J.

Mol Neurodegener. 2016 Sep 29;11(1):66.

8.

Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

Weston PS, Paterson RW, Dickson J, Barnes A, Bomanji JB, Kayani I, Lunn MP, Mummery CJ, Warren JD, Rossor MN, Fox NC, Zetterberg H, Schott JM.

J Alzheimers Dis. 2016 Oct 18;54(4):1297-1302.

9.

Cognitive variability-A marker for incident MCI and AD: An analysis for the Alzheimer's Disease Neuroimaging Initiative.

Anderson ED, Wahoske M, Huber M, Norton D, Li Z, Koscik RL, Umucu E, Johnson SC, Jones J, Asthana S, Gleason CE; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement (Amst). 2016 May 26;4:47-55. doi: 10.1016/j.dadm.2016.05.003. eCollection 2016.

10.

Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus.

Jeppsson A, Höltta M, Zetterberg H, Blennow K, Wikkelsø C, Tullberg M.

Fluids Barriers CNS. 2016 Jul 29;13(1):13. doi: 10.1186/s12987-016-0037-y.

11.

European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow.

Meulenbroek O, O'Dwyer S, de Jong D, van Spijker G, Kennelly S, Cregg F, Olde Rikkert M, Abdullah L, Wallin A, Walsh C, Coen R, Kenny RA, Daly L, Segurado R, Borjesson-Hanson A, Crawford F, Mullan M, Lucca U, Banzi R, Pasquier F, Breuilh L, Riepe M, Kalman J, Molloy W, Tsolaki M, Howard R, Adams J, Gaynor S, Lawlor B.

BMJ Open. 2016 Jul 19;6(7):e011584. doi: 10.1136/bmjopen-2016-011584.

12.

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile.

Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, Masliah E, Rissman RA.

Alzheimers Dement (Amst). 2016 May 7;3:63-72. doi: 10.1016/j.dadm.2016.04.001. eCollection 2016.

13.

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B.

Neurology. 2016 Aug 2;87(5):539-47. doi: 10.1212/WNL.0000000000002923. Epub 2016 Jul 1. Review.

14.

Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients.

Takeda S, Commins C, DeVos SL, Nobuhara CK, Wegmann S, Roe AD, Costantino I, Fan Z, Nicholls SB, Sherman AE, Trisini Lipsanopoulos AT, Scherzer CR, Carlson GA, Pitstick R, Peskind ER, Raskind MA, Li G, Montine TJ, Frosch MP, Hyman BT.

Ann Neurol. 2016 Sep;80(3):355-67. doi: 10.1002/ana.24716. Epub 2016 Aug 3.

PMID:
27351289
15.

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia.

Forlenza OV, Radanovic M, Talib LL, Aprahamian I, Diniz BS, Zetterberg H, Gattaz WF.

Alzheimers Dement (Amst). 2015 Oct 3;1(4):455-63. doi: 10.1016/j.dadm.2015.09.003. eCollection 2015 Dec.

16.

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?

Del Campo Milan M, Zuroff L, Jimenez CR, Scheltens P, Teunissen CE.

Alzheimers Dement (Amst). 2015 Mar 29;1(1):75-80. doi: 10.1016/j.dadm.2014.11.008. eCollection 2015 Mar.

17.

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease.

Sato Y, Bernier F, Yamanaka Y, Aoshima K, Oda Y, Ingelsson M, Lannfelt L, Miyashita A, Kuwano R, Ikeuchi T.

Alzheimers Dement (Amst). 2015 Mar 29;1(1):67-74. doi: 10.1016/j.dadm.2014.11.009. eCollection 2015 Mar.

18.

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.

Kruse N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, Vanderstichele H, El-Agnaf OM, Mollenhauer B.

PLoS One. 2016 Apr 26;11(4):e0153564. doi: 10.1371/journal.pone.0153564. eCollection 2016.

19.

Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.

Ingber AP, Hassenstab J, Fagan AM, Benzinger TL, Grant EA, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2016;52(3):1055-64. doi: 10.3233/JAD-150478.

20.

Monoaminergic neuropathology in Alzheimer's disease.

Šimić G, Babić Leko M, Wray S, Harrington CR, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, de Silva R, Di Giovanni G, Wischik CM, Hof PR.

Prog Neurobiol. 2017 Apr;151:101-138. doi: 10.1016/j.pneurobio.2016.04.001. Epub 2016 Apr 12. Review.

PMID:
27084356

Supplemental Content

Support Center